# Glutamine in Preventing Peripheral Neuropathy in Patients With Multiple Myeloma Receiving Bortezomib

> **NCT01783522** · PHASE2 · TERMINATED · sponsor: **Beth Faiman** · enrollment: 9 (actual)

## Conditions studied

- Chemotherapeutic Agent Toxicity
- Multiple Myeloma
- Peripheral Neuropathy

## Interventions

- **DRUG:** glutamine
- **OTHER:** quality-of-life assessment
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT01783522
- **Lead sponsor:** Beth Faiman
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-02
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Research Cancelled
- **Last updated:** 2019-10-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01783522

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01783522, "Glutamine in Preventing Peripheral Neuropathy in Patients With Multiple Myeloma Receiving Bortezomib". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01783522. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*